BRIEF—New biosimilar rituximab product to launch in Turkey

Following Turkish approval, received in late January, TRPharm’s lead biosimilar Redditux (rituximab) will shortly be launched in the country for the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic lymphoma (CLL).

The product was developed by Dr Reddy’s Laboratories and first approved in India in 2007. In 2016, TRPharm and Dr. Reddy’s announced a collaboration, under the terms of which TRPharm will register and commercialize a total of three biosimilar products from Dr Reddy’s in Turkey.

TRPharm will also manufacture the drug substance and drug product upon completion of its facility investment.